Despite all alternatives, immune checkpoint inhibitors (ICIs) in the treatment of advanced MCC, such as anti-PD-1 inhibitors (pembrolizumab, nivolumab, and retifanlimab) and the anti-PD-L1 inhibitor avelumab, have revolutionized therapies, as they have dramatically improved outcomes for patients with advanced MCC, offering durable responses and better overall survival compared to traditional chemotherapy. Here, CD274 is linked to Merkel cell skin cancer.